Listed

Edwards Lifesciences Corp: Form 10-K for the period ended Dec 31, 2018

Filed with the SEC on Feb 15, 2019 and accepted by EDGAR at Feb 15, 2019, 16:22 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-10-01 to 2018-12-31$977.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue12 months2018-01-01 to 2018-12-31$3.72bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2018-01-01 to 2018-12-31$939.4mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-10-01 to 2018-12-31$743.0mus-gaap:GrossProfit
Gross profit12 months2018-01-01 to 2018-12-31$2.78bnus-gaap:GrossProfit
Research and development12 months2018-01-01 to 2018-12-31$622.2mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2018-01-01 to 2018-12-31$1.09bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2018-01-01 to 2018-12-31$748.2mus-gaap:OperatingIncomeLoss
Interest expense12 months2018-01-01 to 2018-12-31$29.9mus-gaap:InterestExpense
Income tax12 months2018-01-01 to 2018-12-31$39.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-10-01 to 2018-12-31$7.0mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income12 months2018-01-01 to 2018-12-31$722.2mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2018-10-01 to 2018-12-31$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS12 months2018-01-01 to 2018-12-31$3.38us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-10-01 to 2018-12-31$0.03us-gaap:EarningsPerShareBasic
Basic EPS12 months2018-01-01 to 2018-12-31$3.45us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2018-01-01 to 2018-12-31213,600,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2018-01-01 to 2018-12-31$926.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2018-01-01 to 2018-12-31$238.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases12 months2018-01-01 to 2018-12-31$795.5mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2018-12-31$714.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-12-31$2.29bnus-gaap:AssetsCurrent
Total assetsAt period end2018-12-31$5.32bnus-gaap:Assets
Current liabilitiesAt period end2018-12-31$876.6mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2018-12-31$593.8mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2018-12-31$0us-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2018-12-31$3.14bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-19-000004. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.